Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

3.89
Delayed Data
As of 3:59pm ET
 -0.08 / -2.02%
Today’s Change
1.83
Today|||52-Week Range
14.50
+100.52%
Year-to-Date
Pernix: An Investor's Rationale to Staying Long
3:49pm / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close3.97
Today’s open3.81
Day’s range3.80 - 3.98
Volume139,880
Average volume (3 months)621,560
Market cap$37.7M
Dividend yield--
Data as of 3:59pm ET, 03/23/2017

Growth & Valuation

Earnings growth (last year)-198.92%
Earnings growth (this year)+41.73%
Earnings growth (next 5 years)+13.60%
Revenue growth (last year)+44.44%
P/E ratioNM
Price/Sales0.89
Price/Book0.73

Competitors

 Today’s
change
Today’s
% change
TPIVTapImmune Inc+0.38+8.74%
ARGSArgos Therapeutics I...-0.14-16.43%
THLDThreshold Pharmaceut...-0.01-2.10%
INNLInnocoll Holdings PL...-0.15-12.61%
Data as of 3:59pm ET, 03/23/2017

Financials

Last reporting dateMarch 20, 2017
EPS forecast (this quarter)-$3.15
Annual revenue (last year)$175.9M
Annual profit (last year)-$148.3M
Net profit margin-84.34%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
John A. Sedor
President, Chief Financial Officer &
Director
Graham G. Miao
Corporate headquarters
Morristown, New Jersey

Forecasts


Search for Jobs